Your brain isn't recording reality. It's predicting it. Understanding that one shift explains why psychedelics heal, why therapy matters, and why resistance isn't what we think.
All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.
A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point to something “curative,” one expert said.
Merck is racing to defend its leadership in the market for cancer drugs ahead of Keytruda’s looming patent cliff. A clinical ...
Investor's Business Daily on MSN
Merck stock zooms closer to a breakout on 'a new chapter' in cancer
Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.
Go behind the scenes of the Cancer Calculus investigation, and hear insights about Merck's cancer drug Keytruda from ICIJ's ...
Read all the latest news headline updates on cancer drugs. Get all the cancer drugs breaking news updates, videos, photostories and more at Business Standard.
RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 10:00 AM EDTCompany ParticipantsLavina Talukdar - Senior VP ...
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary ...
The gap between US drug prices and those abroad is not a market outcome — it is the result of deliberate political and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results